Zivo Bioscience, Inc.
ZIVO
$14.85
-$0.15-1.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 194.94% | 91.64% | 467.51% | 396.86% | 1,346.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 194.94% | 91.64% | 467.51% | 396.86% | 1,346.34% |
| Cost of Revenue | 212.44% | 116.54% | 572.67% | 530.95% | 5,414.29% |
| Gross Profit | 162.80% | 52.08% | 326.09% | 252.70% | 527.27% |
| SG&A Expenses | -40.05% | 102.45% | 74.24% | 63.11% | 53.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.25% | 147.53% | 85.43% | 71.33% | 54.50% |
| Operating Income | 25.25% | -148.07% | -83.97% | -70.68% | -53.87% |
| Income Before Tax | 26.62% | -130.39% | -72.11% | -60.90% | -52.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.62% | -130.39% | -72.11% | -60.90% | -52.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.62% | -130.39% | -72.11% | -60.90% | -52.48% |
| EBIT | 25.25% | -148.07% | -83.97% | -70.68% | -53.87% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 49.50% | -31.25% | 5.50% | 7.68% | 4.46% |
| Normalized Basic EPS | 49.50% | -31.25% | 5.50% | 7.68% | 4.46% |
| EPS Diluted | 49.50% | -31.25% | 5.50% | 7.68% | 4.46% |
| Normalized Diluted EPS | 49.50% | -31.25% | 5.50% | 7.68% | 4.46% |
| Average Basic Shares Outstanding | 54.85% | 71.22% | 86.16% | 71.40% | 49.27% |
| Average Diluted Shares Outstanding | 54.85% | 71.22% | 86.16% | 71.40% | 49.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |